ASH 2021 Multiple Myeloma News

Ariel JonesConferences | December 17, 2021
This marks the first time a study identified epidemiological and clinical characteristics of SMM in a general population.
Read More
Ariel JonesConferences | December 17, 2021
Researchers evaluated real-world data on DVd for treatment of patients with relapsed or refractory multiple myeloma.
Ariel JonesConferences | December 11, 2021
Both are malignancies associated with significant immunoparesis.
Ariel JonesConferences | December 11, 2021
Fabio Efficace, PhD, and a team of researchers investigated IMWG frailty scoring in patients with previously treated disease.
Ariel JonesConferences | December 11, 2021
Researchers explored whether screening for MGUS could increase the frequency of patients with MM being diagnosed.
Ariel JonesConferences | December 11, 2021
This is according to findings from a phase III study presented during the 2021 ASH Annual Meeting.
Ariel JonesConferences | December 10, 2021
The findings report results from 24 months of maintenance therapy and were presented at the ASH Annual Meeting 2021.
Ariel JonesConferences | December 10, 2021
Updates from this trial were presented at the 63rd American Society of Hematology Annual Meeting & Exhibition.
Advertisement
Advertisement